A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Removille, Nathalie ^a   Origer, Alain ^a   Couffignal, Sophie ^a   Vaillant, Michel ^a   Schmit, Jean Claude ^b   Lair, Marie Lise ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; EPIDEMIOLOGY; FEMALE; HEALTH SURVEY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUXEMBOURG; MALE; MULTICENTER STUDY; PREVALENCE; RISK FACTOR; RISK REDUCTION; SUBSTANCE ABUSE;

ADOLESCENT; FEMALE; HEALTH SURVEYS; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HIV INFECTIONS; HUMANS; LUXEMBOURG; MALE; PREVALENCE; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 79956029367     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-351     Document Type: Article

References (31)

1. Annual report 2003. The state of the drugs problem in the European Union and Norway. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon
2. -2010 Annual report on the state of the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon 2010
3. Annual report 2005. The state of the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon
4. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. G Quaglio F Lugoboni B Pajusco M Sarti G Talamini A Lechi P Mezzelani DC Des Jarlais, Clin Infect Dis 2003 37 1 33 40 10.1086/375566 12830406 (Pubitemid 36836642)
5. Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy. L Camoni V Regine MC Salfa G Nicoletti P Canuzzi N Magliocchetti G Rezza B Suligoi, Ann Ist Super Sanita 46 1 59 65
6. Prevalence of Serologic Markers of HBV, HDV, HCV and HIV in Non-Injection Drug Users Compared to Injection Drug Users in Gran Canaria, Spain. MLMG Otilia Evora Santana Rodríguez Santana Juan Francisco Hernández Cãal José María Limĩana Sánchez Antonio Manuel Martín, European journal of epidemiology 1998 14 6 555 561 10.1023/A:1007410707801 9794122
7. Etude épidémiologique des infections HIV et l'hépatite virale C dans les prisons luxembourgeoises. J Schlink, Luxembourg: Centre Pénitentiaire Luxembourg 1999 21538184
8. L'état du phénomène de la drogue au Grand-Duché de Luxembourg. Réseau National d'Information sur les Stupéfiants et les Toxicomanies (R.E.L.I.S). ed.2005. Luxembourg. A Origer, Point focal OEDT Luxembourg - CRP-Santé 2005
9. Drug epidemiology in the European institutions: historical background and key indicators. LR Hartnoll, Bulletin on Narcotics 2003 1-2 55 53 71
10. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? A Taylor D Goldberg S Hutchinson S Cameron SM Gore J McMenamin S Green A Pithie R Fox, The Journal of infection 2000 40 2 176 183 10.1053/jinf.2000.0647 10841096 (Pubitemid 30312558)
11. L'état du phénomène de la drogue au Grand-Duché de Luxembourg. Réseau National d'Information sur les Stupéfiants et les Toxicomanies (R.E.L.I.S). ed.2006. Luxembourg. A Origer, Point focal OEDT Luxembourg - CRP-Santé 2006
12. Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence. A Origer JC Schmit, J Epidemiol Community Health
13. Suchtpräventioun an der Gemeng". Entwicklung, Durchführung und Evaluation eines Modells zur gemeindeorientierten Suchtprävention. UC Fischer W Krieger, Luxembourg: Centre de prévention des toxicomanies 1999
14. Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. F Roman K Hawotte D Struck AM Ternes JY Servais V Arendt P Hoffman R Hemmer T Staub C Seguin-Devaux, et al. World J Gastroenterol 2008 14 8 1237 1243 10.3748/wjg.14.1237 18300350 (Pubitemid 351356332)
15. Study on HCV, HBV and HIV seroprevalence in a sample of drug users in contact with treatment centres or in prisons in Belgium. S Plasschaert L Ameye T De Clercq, 2004
16. "The first shot": the context of first injection of illicit drugs, ongoing injecting practices, and hepatitis C infection in Rio de Janeiro, Brazil. ML Oliveira MA Hacker SA Oliveira PR Telles KM O CF Yoshida FI Bastos, Cadernos de saude publica/Ministerio da Saude, Fundacao Oswaldo Cruz, Escola Nacional de Saude Publica 2006 22 4 861 870 16612439 (Pubitemid 43657130)
17. Natural history of hepatitis C. DL Thomas LB Seeff, Clinics in liver disease 2005 9 3 383 398 vi 10.1016/j.cld.2005.05.003 16023972 (Pubitemid 40968202)
18. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. ML Shiffman F Suter BR Bacon D Nelson H Harley R Sola SD Shafran K Barange A Lin A Soman, et al. N Engl J Med 2007 357 2 124 134 10.1056/NEJMoa066403 17625124 (Pubitemid 47057730)
19. European Monitoring Centre for Drugs and Drug Addiction. http://www.emcdda.europa.eu/stats10/inftab3
20. Factors associated with exposure to hepatitis B virus in injection drug users. M Backmund K Meyer C Schuetz J Reimer, Drug and alcohol dependence 2006 84 2 154 159 10.1016/j.drugalcdep.2006.01.009 16481128 (Pubitemid 44119092)
21. Hepatitis C transmission - where are we now? A Clarke R Kulasegaram, International journal of STD & AIDS 2006 17 2 74 80 quiz 80 10.1258/095646206775455685 21559435
22. Prevalence of and risk factors for hepatitis B virus infection among street-recruited young injection and non-injection heroin users in Barcelona, Madrid and Seville. F Vallejo C Toro L de la Fuente MT Brugal V Soriano TC Silva MJ Bravo R Ballesta G Barrio, European addiction research 2008 14 3 116 124 10.1159/000130415 18552487 (Pubitemid 351841863)
23. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. DR Gibson NM Flynn D Perales, AIDS (London, England) 2001 15 11 1329 1341 10.1097/00002030-200107270-00002 (Pubitemid 32662285)
24. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. SA Villano D Vlahov KE Nelson CM Lyles S Cohn DL Thomas, Journal of clinical microbiology 1997 35 12 3274 3277 9399533 (Pubitemid 27505758)
25. Management of occupational exposures to blood-borne viruses. JL Gerberding, N Engl J Med 1995 332 7 444 451 10.1056/NEJM199502163320707 7824017
26. Rapport D'activité 2009. Cdsd SIDA, Luxembourg: Comité de surveillance du SIDA 2010
27. Sharing of drug preparation equipment as a risk factor for hepatitis C. H Hagan H Thiede NS Weiss SG Hopkins JS Duchin ER Alexander, American journal of public health 2001 91 1 42 46 11189822 (Pubitemid 32049265)
28. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. LE Thorpe LJ Ouellet R Hershow SL Bailey IT Williams J Williamson ER Monterroso RS Garfein, Am J Epidemiol 2002 155 7 645 653 10.1093/aje/155.7.645 11914192 (Pubitemid 34246097)
29. Oral presentation on the European expert meeting on key indicator Drug Related Infectious Diseases. Center for Disease Control, EMCDDA-Lisbon 2003 Oct 20-21
30. Current trends in HIV/ AIDS epidemiology in Poland, 1999 - 2004. M Rosinska, Euro Surveill 2006 11 4
31. European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) - the need to improve quality and comparability. L Wiessing B Guarita I Giraudon H Brummer-Korvenkontio M Salminen SA Cowan, Euro Surveill 2008 13 21